Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the FDA clearance of its latest device, the TensWave, designed to cater specifically to patients and insurance carriers that reimburse only for Transcutaneous Electrical Nerve Stimulation (TENS) therapy. CEO Thomas Sandgaard shared the news with Steve Darling from Proactive, emphasizing the company’s ongoing commitment to innovation in pain management. The TensWave device, available by prescription, is user-friendly and portable, making it easy for patients to integrate into their daily routines. It provides effective pain relief through TENS therapy, a method clinically proven to alleviate both chronic and acute pain without the use of medication. While the TensWave offers a more focused solution, it is not intended to replace Zynex’s market-leading NexWave electrotherapy device. Instead, it provides an additional option that offers flexibility for patients dealing with specific insurance coverage limitations. This new device continues Zynex’s tradition of delivering advanced solutions to improve the quality of life for those suffering from pain, further solidifying its position as a leader in the pain management industry. #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #q2 #finanacials #PainManagement #FDAApproval #TensWave #MedicalDevices #HealthcareSolutions #ThomasSandgaard #ChronicPain #Healthcare #InvestingInHealthcare #NextWave #TENS #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews